M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

Yoshiaki Kubota, Keiyo Takubo, Takatsune Shimizu, Hiroaki Ohno, Kazuo Kishi, Masabumi Shibuya, Hideyuki Saya, Toshio Suda

Research output: Contribution to journalArticlepeer-review

320 Citations (Scopus)


Antiangiogenic therapy for the treatment of cancer and other neovascular diseases is desired to be selective for pathological angiogenesis and lymphangiogenesis. Macrophage colony-stimulating factor (M-CSF), a cytokine required for the differentiation of monocyte lineage cells, promotes the formation of high-density vessel networks in tumors and therefore possesses therapeutic potential as an M-CSF inhibitor. However, the physiological role of M-CSF in vascular and lymphatic development, as well as the precise mechanisms underlying the antiangiogenic effects of M-CSF inhibition, remains unclear. Moreover, therapeutic potential of M-CSF inhibition in other neovascular diseases has not yet been evaluated. We used osteopetrotic (op/op) mice to demonstrate that M-CSF deficiency reduces the abundance of LYVE-1+ and LYVE1- macrophages, resulting in defects in vascular and lymphatic development. In ischemic retinopathy, M-CSF was required for pathological neovascularization but was not required for the recovery of normal vasculature. In mouse osteosarcoma, M-CSF inhibition effectively suppressed tumor angiogenesis and lymphangiogenesis, and it disorganized extracellular matrices. In contrast to VEGF blockade, interruption of M-CSF inhibition did not promote rapid vascular regrowth. Continuous M-CSF inhibition did not affect healthy vascular and lymphatic systems outside tumors. These results suggest that M-CSF-targeted therapy is an ideal strategy for treating ocular neovascular diseases and cancer.

Original languageEnglish
Pages (from-to)1089-1102
Number of pages14
JournalJournal of Experimental Medicine
Issue number5
Publication statusPublished - 2009 May 11

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis'. Together they form a unique fingerprint.

Cite this